U.S. Markets open in 2 hrs 32 mins

Aerie Pharmaceuticals, Inc. (AERI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
10.36+0.47 (+4.75%)
At close: 04:00PM EST
10.13 -0.23 (-2.22%)
Pre-Market: 06:29AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close9.89
Bid0.00 x 1000
Ask0.00 x 1100
Day's Range9.81 - 10.42
52 Week Range9.15 - 21.30
Avg. Volume894,545
Market Cap485.815M
Beta (5Y Monthly)0.87
PE Ratio (TTM)N/A
EPS (TTM)-3.83
Earnings DateMay 05, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.27
  • Business Wire

    Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences

    DURHAM, N.C., November 09, 2021--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that the Benjamin McGraw, III, Pharm.D., Interim Executive Chairman, will participate in the following virtual investor conferences.

  • Motley Fool

    Aerie Pharmaceuticals, inc (AERI) Q3 2021 Earnings Call Transcript

    Thank you for standing by, and welcome to the Aerie Pharmaceuticals Third Quarter 2021 Earnings Conference Call. It is now my pleasure to turn the floor over to Aerie's General Counsel, John LaRocca. With us today are Ben McGraw, Aerie's Interim Executive Chairman; Tom Mitro, Aerie's President and Chief Operating Officer; David Hollander, Aerie's Chief Research and Development Officer; Casey Kopczynski, Aerie's Chief Scientific Officer; and Jeff Calabrese, Aerie's Vice President of Finance and Principal Accounting Officer.

  • Zacks

    Aerie's (AERI) Q3 Earnings Miss Estimates, Revenues Rise Y/Y

    Aerie (AERI) incurs wider-than-expected loss in the third quarter of 2021 while sales match expectations.